Table 1.

Baseline demographics and clinical characteristics of patients infected by SARS-CoV-2 and association between these characteristics and mortality.

Characteristic	Number (proportion) unless specified otherwise
Age, median age in years, (min–max)	57.7 (5.2–72.8)
Male sex	32 (57.1)
CAR T-cell therapy indication
B-cell acute lymphoblastic leukemia	7 (12.5)
B-cell non-Hodgkin lymphoma	46 (82.1)
Multiple myeloma	3 (5.4)
Disease status at time of COVID-19 diagnosis
Relapse/progression	14 (15)
Partial response	7 (12.5)
Complete remission	35 (62.5)
Metabolic comorbidities (obesity, hypertension, diabetes, hypercholesterolemia, smoking, and cardiovascular disease)
Yes	18 (32.1)
No	38 (67.9)
Lansky/Karnofsky-score at time of COVID-19 diagnosis
<70	10 (17.9)
≥70	46 (82.1)
Oxygen therapy
No oxygen support needed,	32 (57.1)
Oxygen support needed	24 (42.9)
Invasive mechanical ventilation	16 (28.6)
Noninvasive ventilation (noninvasive positive pressure ventilation)	2 (3.6)
COVID-19 treatment
Dexamethasone	10 (17.9)
(Methyl)prednisolone	2 (3.6)
Tocilizumab	8 (14.3)
Baricitinib	2 (3.6)
Eculizumab	1 (1.8)
Remdesivir	20 (35.7)
Lopinavir/Ritonavir	1 (1.8)
Chloroquine/Hydroxychloroquine	1 (1.8)
Convalescent plasma	17 (30.4)
IVIG non-SARS-CoV-2	1 (1.8)
Anticoagulants (either prophylaxis or treatment)	19 (33.9)
No treatment	15 (26.8)
Resolution of COVID-19 in surviving patients
Clinical resolution	10 (17.9)
Virologic (PCR) resolution	21 (37.5)
Clinical COVID-19 median duration, days (min–max)	20.0 (0–157)
Virologic COVID-19 median duration, days (min–max)	48 (6–113)
Factors associated with mortality (HR, 95% CI, P value)
Age at time of COVID-19	1.39 (1.05–1.86), p = 0.02
Performance status at time of COVID-19	0.71 (0.56–0.89), p = 0.003
Metabolic comorbidity	2.75 (1.19–6.35), p = 0.02
Tumor not in complete remission at time of COVID-19	2.40 (1.04–5.55), p = 0.04